Sustained clinical response rates of 66.7 percent with ridinilazole vs. 42.4 persent with vancomycin

Divestment further sharpens company’s focus. on three main therapy areas

Announces U.S. FDA orphan drug designation

VBI Vaccines presents new data supporting its glioblastoma immunotherapy program at the ESMO Symposium on Immuno-Oncology

Global task force tackles problem of untreatable cancers and disease relapse: non-toxic chemicals in plants and foods may be key

GBM AGILE (An Adaptive, Global, Innovative Learning Environment) to implement unprecedented international clinical trial

Hastings Center awarded NIH grant for major project on goals and practices of next-generation prenatal testing

New findings open opportunities for creating new medicines for metabolic, musculoskeletal, autoimmune and other age-related diseases

F-star partners with BMS on potential treatment of HER2-positive cancers

Ultragenyx reports positive results from Phase 2 study of UX007 in long-chain fatty acid oxidation disorder patients

Caladrius Biosciences and Sanford Research establish strategic collaboration to drive major advance in treatment of type 1 diabetes

The 2015 installment of the American Society for Cell Biology's annual meeting